Optimizing topical management of atopic dermatitis

Annals of Allergy, Asthma & Immunology

May  2022  Volume 128, Issue 5 Pages 488-504  CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to

  • Discuss optimal utilization of currently available topical medications for children and adults with atopic dermatitis and recognize the steps that must be taken in considering whether to advance to systemic therapy for moderate-to-severe atopic dermatitis exacerbation that may not be controlled with topical corticosteroids alone.
  • Compare the relative risks and benefits of systemic immunosuppressants vs. biologics vs. JAK inhibitors for treatment.
Additional information
Disclosure: 

Disclosure Statement
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients.

Examples of such organizations include:

  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Planner:

  • Donald Y.M. Leung, MD, PhD, Consultant; Boehringer Ingelheim, Evommune, Inc., Genentech Inc., Incyte, Leo Pharmaceuticals

Authors:

  • Sneha Butala, MD, has no relevant financial relationships with ineligible companies to disclose.
  • Amy S. Paller, MS, MD, Consultant: AbbVie, Almirall, Arcutis, Arena, BiomX, Bristol Myers Squibb, Catawba, Eli Lilly, Gilead, Incyte, Janssen, Leo, Novartis, Pfizer, RAPT, Regeneron, Sanofi/Genzyme, Seanergy; Researcher: AbbVie, Eli Lilly, Incyte, Regeneron
    Recognition of Commercial Support: This activity has not received external commercial support.
    Copyright Statement: © 2015-2022 ACAAI. All rights reserved.
    CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at education@acaai.org or 847-427-1200.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
05/01/2022
Course expires: 
04/30/2024
Rating: 
0

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.